At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIVI BioVie Inc
Closed Good Friday 04-17 16:00:00 EDT
0.8408
+0.0476
+6.00%
盘后0.8196
-0.0212-2.52%
19:34 EDT
| High0.8500 | Low0.7601 | Vol54.24K |
| Open0.7900 | D1 Closing0.7932 | Amplitude11.33% |
| Mkt Cap15.51M | Tradable Cap13.49M | Total Shares18.45M |
| T/O43.96K | T/O Rate0.34% | Tradable Shares16.04M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
BRIEF-Biovie Initiates Sunrise-Pd Clinical Trial Assessing Bezisterim In Early Parkinson’S Disease With First Patient Enrolled
Reuters · 04-16 12:27
BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled
GlobeNewswire · 04-16 12:00
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice President Tyler Korman - as Sponsored Programming
ACCESS Newswire · 04-11
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc.
ACCESS Newswire · 03-29
BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025
GlobeNewswire · 03-27
New to The Street's FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese's The Big Skinny on eXoZymes, and Banzai CEO Joe Davy
ACCESS Newswire · 03-24
New to The Street Show 633 to Broadcast on Fox Business Network as Sponsored Programming Tonight at 10:30 PM PST Featuring Zapp Electric Vehicles ($ZAPP), BioVie ($BIVI), PetVivo ($PETV), and Banzai ($BNZI)
ACCESS Newswire · 03-10
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce
ACCESS Newswire · 03-04
New to The Street to Broadcast Live on Bloomberg Tonight at 6:30 PM EST as Sponsored Programming, Spotlighting BioVie (BIVI), RoadZen (RDZN), HPB, and Sustainable Innovation With Shark Tank’s Kevin Harrington and Sustainable Green Team (SGTM)
ACCESS Newswire · 02-22
Is BioVie (NASDAQ:BIVI) In A Good Position To Invest In Growth?
Simply Wall St. · 02-13
BioVie files to sell 7.71M shares of common stock for holders
seekingalpha · 2024-11-21
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
GlobeNewswire · 2024-11-20
BioVie says Parkinson’s Disease clinical trial is fully funded
TIPRANKS · 2024-11-04
BioVie Inc - Raises Over $15 Million From Secondary Offerings
THOMSON REUTERS · 2024-11-04
BioVie Inc - Pd-202 Trial Expected to Start Early 2025, Results by Late 2025
THOMSON REUTERS · 2024-11-04
BioVie’s Upcoming Parkinson’s Disease Clinical Trial Is Fully Funded
THOMSON REUTERS · 2024-11-04
BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded
GlobeNewswire · 2024-11-04
BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded
BioVie Inc. Announces Closing of Registered Direct Offering
THOMSON REUTERS · 2024-10-29
BioVie Inc. Announces Closing of Registered Direct Offering
GlobeNewswire · 2024-10-29
BRIEF-BioVie Announces Pricing Of Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Reuters · 2024-10-28
Introduction
Company Name.
BioVie Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App